Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/145647
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorMarchena, Migueles_ES
dc.contributor.authorVillarejo-Zori, Beatrizes_ES
dc.contributor.authorZaldívar-Díez, Josefaes_ES
dc.contributor.authorPalomo, Vallees_ES
dc.contributor.authorGil, Carmenes_ES
dc.contributor.authorHernández-Sánchez, Catalinaes_ES
dc.contributor.authorMartínez Gil, Anaes_ES
dc.contributor.authorDe la Rosa, Enrique J.es_ES
dc.date.accessioned2017-02-23T11:17:00Z-
dc.date.available2017-02-23T11:17:00Z-
dc.date.issued2017-01-23-
dc.identifier.citationJournal of Enzyme Inhibition and Medicinal Chemistry 32 (1) 522-526 (2017)es_ES
dc.identifier.issn1475-6366-
dc.identifier.urihttp://hdl.handle.net/10261/145647-
dc.description6 p.-5 fig.es_ES
dc.description.abstractRetinitis pigmentosa (RP) is an inherited retinal dystrophy that courses with progressive degeneration of retinal tissue and loss of vision. Currently, RP is an unpreventable, incurable condition. We propose glycogen synthase kinase 3 (GSK-3) inhibitors as potential leads for retinal cell neuroprotection, since the retina is also a part of the central nervous system and GSK-3 inhibitors are potent neuroprotectant agents. Using a chemical genetic approach, diverse small molecules with different potency and binding mode to GSK-3 have been used to validate and confirm GSK-3 as a pharmacological target for RP. Moreover, this medicinal chemistry approach has provided new leads for the future disease-modifying treatment of RP.es_ES
dc.description.sponsorshipThis work has been partially funded by the Spanish MINECO grants (SAF2012-37979-C03-01 to AM and SAF2013-41059-R to EJdlR).es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.subjectGSK-3 inhibitorses_ES
dc.subjectRetinal diseaseses_ES
dc.subjectRetinitis pigmentosaes_ES
dc.subjectGlaucomaes_ES
dc.titleSmall molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosaes_ES
dc.typeartículoes_ES
dc.identifier.doi10.1080/14756366.2016.1265522-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1080/14756366.2016.1265522es_ES
dc.identifier.e-issn1475-6374-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.pmid28114834-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
J.Enz. Inhibit. Med. Chem. 2017.pdfArtículo principal1,13 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

PubMed Central
Citations

12
checked on 20-mar-2024

SCOPUSTM   
Citations

19
checked on 23-mar-2024

WEB OF SCIENCETM
Citations

19
checked on 22-feb-2024

Page view(s)

305
checked on 28-mar-2024

Download(s)

290
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons